New Approaches against Metastatic Breast Cancer: Mini-Tumors from Circulating Tumor Cells On January 3, 2025, the German Cancer Research Center (DKFZ) published an exciting press release on the results of...

EvoPAR-Breast01 Study STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY WITH SARUPARIB AND CAMIZESTRANT IN THE TREATMENT OF PATIENTS WITH HER2-NEGATIVE, ER-POSITIVE, ADVANCED BREAST CANCER Die EvoPAR-Breast01...

CAPItello-292 Study THERAPY STUDY TO EVALUATE A NEW COMBINATION THERAPY WITH CAPIVASERTIB, FULVESTRANT AND A CDK4/6 INHIBITOR IN PATIENTS WITH HER2-NEGATIVE, HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER Die CAPItello-292 ist eine...

New Approaches against Metastatic Breast Cancer: Mini-Tumors from Circulating Tumor Cells On January 3, 2025, the German Cancer Research Center (DKFZ) published an exciting press release on the results of...

CAMBRIA-2 Study THERAPEUTIC STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT IN THE TREATMENT OF PATIENTS WITH ER-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER Die CAMBRIA-2 ist eine offene (behandelnde Ärzt:innen...

CAMBRIA-1 Study THERAPY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT IN THE TREATMENT OF PATIENTS WITH ER-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER Die CAMBRIA-1 ist eine offene (behandelnde Ärzt:innen...

  Breast Cancer Study Showed Improved Progression-Free Survival in Advanced HR+, HER2- Breast Cancer A new Phase III breast cancer study, led by Dr. Kümmel, shows promising results for the...

EPIK-B5 Study This study can enroll adult men and postmenopausal women with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation Breast cancer has various classifications, including by stage or...

EMBER-4 Study Endocrine therapy with Imlunestrant in high-risk patients with early ER-positive and HER2-negative breast cancer and completed endocrine therapy EMBER-4 is a randomized, unblinded (patients and physicians know the...

Prof. Kümmel – Methadone for Cancer?

SERENA-6 Study Therapy study to evaluate the potential additional efficacy and safety of Camizestrant in the first-line treatment of patients with HER2-negative, HR-positive, ESR1-mutated breast cancer Study recruitment was completed...

Change from July 1 – Mammography Screening also for Women Aged 70-75 From July 1, 2024, the mammography screening program for early detection of breast cancer will...

Prof. Janni from Ulm University Hospital presented the SURVIVE study to us at the Post-ASCO, the 25th NOGGO Gynecological Oncology Update in Berlin. It summarized the most important and latest...

Merck announced that the Phase 3 KEYNOTE-522 study of Keytruda (anti-PD-1 therapy) met its overall survival endpoint in high-risk early-stage triple-negative breast cancer (TNBC). In combination with chemotherapy as a...

TROPION-Breast04 Study Therapy with antibody-drug conjugate and immunotherapy or standard therapy in previously untreated patients with early-stage triple-negative breast cancer TROPION-Breast04 is a randomized (treatment assignment for the specific patient...

TROPION-Breast03 Study Antibody-drug conjugate therapy with or without immunotherapy in patients with triple-negative and early breast cancer and residual tumor in the breast or axilla after neoadjuvant chemotherapy and completed...

MINERVA Study Combination therapy with Abemaciclib and endocrine therapy in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer with a focus on digital side effect management https://youtu.be/MRxnbZA1Kn8...

SURVIVE Study Breast cancer aftercare study for women and men with early-stage breast cancer, comparing standard aftercare with intensified aftercare https://www.youtube.com/watch?v=5EhOeRa2CJo&ab_channel=ForumGynOnkologie What is being investigated in this study? The SURVIVE...

DESTINY-Breast11 Study Therapy with antibody-drug conjugate alone or before chemotherapy plus antibodies compared to chemotherapy plus antibodies in high-risk patients with early-stage HER2-positive breast cancer Study recruitment was completed in...

ADAPTlate Study Personalized therapy study in patients with hormone receptor-positive, HER2 receptor-negative early-stage breast cancer who have a clinically or genomically high risk of late recurrence The ADAPTlate is a...

PHERGain-2 Study A PHASE 2 STUDY TO EVALUATE THE EFFICACY OF A CHEMOTHERAPY-FREE STRATEGY WITH SUBCUTANEOUS FIXED-DOSE TRASTUZUMAB, PERTUZUMAB, AND T-DM1 IN PATIENTS WITH PREVIOUSLY UNTREATED, HER2-POSITIVE EARLY BREAST CANCER...

PROVIDENCE Study A non-interventional study to collect clinical and quality of life data in patients with HER2+ or HER2-low inoperable or metastatic breast cancer who receive trastuzumab deruxtecan as second-line...

DESTINY-Breast05 / GBG-103 Immunotherapy with antibody-drug conjugates in high-risk patients with early, HER2-positive breast cancer and residual tumor after completed chemotherapy, antibody treatment, and surgery Study recruitment was completed in...

GeparPiPPa / GBG-105 THERAPY STUDY TO EVALUATE THE POTENTIAL ADDITIONAL EFFICACY AND SAFETY OF INAVOLISIB IN THE PRE-OPERATIVE TREATMENT OF PATIENTS WITH HER2-POSITIVE, HR-POSITIVE, PIK3CA-MUTATED EARLY BREAST CANCER. GeparPiPPa is...

New Approval for the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer Currently, the treatment of metastatic breast cancer that is hormone receptor-positive (HR+) and does not express human epidermal growth...

PROOFS – Registry Study A REGISTRY STUDY FOR LONG-TERM FOLLOW-UP OF PATIENTS WITH EARLY-STAGE LUMINAL BREAST CANCER WHO ARE TREATED WITH ENDOCRINE THERAPY PLUS OVARIAN FUNCTION SUPPRESSION (OFS) OR STANDARD...